Neurological aspects of medical use of cannabidiol.

CONCLUSIONS: Pre-clinical evidence largely shows that CBD can produce beneficial effects in AD, PD and MS patients, but its employment for these disorders needs further confirmation from well designed clinical studies. CBD pre-clinical demonstration of antiepileptic activity is supported by recent clinical studies in human epileptic subjects resistant to standard antiepileptic drugs showing its potential use in children and young adults affected by refractory epilepsy. Evidence for use of CBD in PD is still not supported by sufficient data whereas only a few studies including a small number of patients are available.
PMID: 28412918 [PubMed - as supplied by publisher]

Source: CNS and Neurological Disorders Drug Targets - April 13, 2017 Category: Drugs & Pharmacology Authors: Mannucci C, Navarra M, Calapai F, Spagnolo EV, Busardò FP, Da Cas R, Ippolito FM, Calapai G Tags: CNS Neurol Disord Drug Targets Source Type: research